CR20120026A - Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv - Google Patents

Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv

Info

Publication number
CR20120026A
CR20120026A CR20120026A CR20120026A CR20120026A CR 20120026 A CR20120026 A CR 20120026A CR 20120026 A CR20120026 A CR 20120026A CR 20120026 A CR20120026 A CR 20120026A CR 20120026 A CR20120026 A CR 20120026A
Authority
CR
Costa Rica
Prior art keywords
hpv
prevention
disease
virus protein
new constructions
Prior art date
Application number
CR20120026A
Other languages
English (en)
Inventor
Guy Jean Marie Fernand Pierre Baudoux
Brigitte Desiree Alberte Colau
Najoua Dendouga
Sandra Giannini
Nicolas Pierre Fernand Lecrenier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CR20120026A publication Critical patent/CR20120026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La divulgación proporciona construcciones novedosas de proteína del virus de papiloma humano (HPV) y su uso en la prevención de la enfermedad por el HPV. Las construcciones son proteínas quiméricas que comprenden proteínas L1 con un péptido L2 de HPV insertado en la proteína L1.
CR20120026A 2009-06-25 2012-01-16 Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv CR20120026A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22035809P 2009-06-25 2009-06-25
US23988009P 2009-09-04 2009-09-04
US32210210P 2010-04-08 2010-04-08

Publications (1)

Publication Number Publication Date
CR20120026A true CR20120026A (es) 2012-04-13

Family

ID=43014491

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120026A CR20120026A (es) 2009-06-25 2012-01-16 Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv

Country Status (20)

Country Link
US (1) US20120087937A1 (es)
EP (1) EP2445525A2 (es)
JP (1) JP2012530505A (es)
KR (1) KR20120098580A (es)
CN (1) CN102497880A (es)
AU (1) AU2010264695A1 (es)
BR (1) BRPI1014718A2 (es)
CA (1) CA2768172A1 (es)
CL (1) CL2011003271A1 (es)
CO (1) CO6480995A2 (es)
CR (1) CR20120026A (es)
DO (1) DOP2011000396A (es)
EA (1) EA022213B1 (es)
IL (1) IL217094A0 (es)
MA (1) MA33440B1 (es)
MX (1) MX2011013744A (es)
PE (1) PE20120563A1 (es)
SG (1) SG177269A1 (es)
WO (1) WO2010149752A2 (es)
ZA (1) ZA201109453B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2653251T3 (es) * 2009-04-10 2018-02-06 The Johns Hopkins University Partículas de tipo papilomavirus (VLP) como vacunas de amplio espectro del virus del papiloma humano (VPH)
EP2785842A4 (en) * 2011-12-01 2015-11-25 Univ Cape Town HPV CHIMERE PARTICLE
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
CN103864936B (zh) * 2012-12-11 2018-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途
EP2940133A4 (en) * 2012-12-25 2016-07-06 Chemo Sero Therapeut Res Inst VACCINE AGAINST HPV AND / OR HEPATITIS B INFECTION CONTAINING CHIMERIC HPV / HBS PROTEIN AS AN ACTIVE INGREDIENT
CN117187262A (zh) * 2014-02-18 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
US10238729B2 (en) 2014-10-24 2019-03-26 Hpvvax, Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
WO2017092710A1 (zh) * 2015-12-04 2017-06-08 厦门大学 一种人乳头瘤病毒58型l1蛋白的突变体
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
CN107188967B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN109251235B (zh) * 2017-07-14 2021-04-27 厦门大学 一种人乳头瘤病毒16型l1蛋白的突变体
CN110950935A (zh) * 2018-09-26 2020-04-03 厦门大学 一种人乳头瘤病毒51型l1蛋白的突变体
CN114127097A (zh) * 2019-07-19 2022-03-01 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
WO2021013067A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
WO2021013077A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒58型l1蛋白
CN111944834A (zh) * 2020-09-04 2020-11-17 吉林医药学院 人乳头瘤病毒16型表位嵌合l1的重组载体、重组蛋白、病毒样颗粒及其制备和应用
CN112300290B (zh) * 2020-09-30 2022-04-01 北京康乐卫士生物技术股份有限公司 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗
CN114716562B (zh) * 2021-01-04 2023-11-10 中国医学科学院基础医学研究所 一种人乳头瘤病毒58型嵌合蛋白及其用途
CN114716561B (zh) * 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716560B (zh) * 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
PT1012348E (pt) 1997-09-16 2002-11-29 Innogenetics Nv Deteccao do virus do papiloma humano por pcr e hibridacao reversa tipo-especifica
PT1126876E (pt) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Sistemas adjuvantes e vacinas
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
JP2004538010A (ja) 2001-08-08 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アッセイ
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1506222E (pt) * 2002-05-17 2009-06-12 Univ Cape Town Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas
GB0228715D0 (en) 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
CN101193653B (zh) 2005-02-01 2013-03-27 美国政府健康及人类服务部 用于诱导广泛交叉中和抗体的乳头瘤病毒l2 n末端肽
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原
MX2009014246A (es) 2007-06-26 2010-03-31 Japan Health Science Found Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
AP2010005284A0 (en) * 2007-11-02 2010-06-30 Univ Johns Hopkins Multitype HPV peptide compositions and methods fortreatment or prevention of human papillomavirus i nfection
AU2009275909A1 (en) 2008-07-31 2010-02-04 Glaxosmithkline Biologicals S.A. Vaccine against HPV

Also Published As

Publication number Publication date
DOP2011000396A (es) 2012-02-15
PE20120563A1 (es) 2012-05-17
WO2010149752A3 (en) 2011-03-31
BRPI1014718A2 (pt) 2016-04-12
US20120087937A1 (en) 2012-04-12
KR20120098580A (ko) 2012-09-05
CN102497880A (zh) 2012-06-13
CO6480995A2 (es) 2012-07-16
ZA201109453B (en) 2012-08-29
CA2768172A1 (en) 2010-12-29
SG177269A1 (en) 2012-02-28
MA33440B1 (fr) 2012-07-03
IL217094A0 (en) 2012-02-29
MX2011013744A (es) 2012-09-28
EA201190327A1 (ru) 2012-07-30
WO2010149752A2 (en) 2010-12-29
JP2012530505A (ja) 2012-12-06
EP2445525A2 (en) 2012-05-02
EA022213B1 (ru) 2015-11-30
CL2011003271A1 (es) 2012-08-31
AU2010264695A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
EA201171494A1 (ru) Миметики белка smac
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
WO2016070166A3 (en) Messenger una molecules and uses thereof
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CU24043B1 (es) Hormona foliculoestimulante humana recombinante, composición farmacéutica que la comprende
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
MY189334A (en) Lentiviral vector-based japanese encephalitis immunogenic composition
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof